AustralianSuper Pty Ltd Acquires 92,959 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

AustralianSuper Pty Ltd raised its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 49.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 282,739 shares of the biotechnology company's stock after acquiring an additional 92,959 shares during the quarter. AustralianSuper Pty Ltd owned about 0.63% of United Therapeutics worth $87,160,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Cerity Partners LLC increased its position in United Therapeutics by 30.4% in the 4th quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company's stock valued at $4,098,000 after acquiring an additional 2,702 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in United Therapeutics by 11.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock valued at $1,129,000 after acquiring an additional 376 shares in the last quarter. Korea Investment CORP grew its position in shares of United Therapeutics by 6.2% during the 4th quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock worth $13,863,000 after buying an additional 2,300 shares during the period. Concurrent Investment Advisors LLC acquired a new stake in shares of United Therapeutics during the 1st quarter worth approximately $227,000. Finally, Nepsis Inc. grew its position in shares of United Therapeutics by 6.7% during the 1st quarter. Nepsis Inc. now owns 58,574 shares of the biotechnology company's stock worth $18,057,000 after buying an additional 3,653 shares during the period. Institutional investors and hedge funds own 94.08% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Cantor Fitzgerald assumed coverage on shares of United Therapeutics in a research report on Monday, June 2nd. They set an "overweight" rating and a $405.00 price target for the company. Wells Fargo & Company reiterated an "equal weight" rating and set a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. HC Wainwright reiterated a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a research report on Monday, May 5th. UBS Group reduced their price objective on shares of United Therapeutics from $410.00 to $385.00 and set a "buy" rating on the stock in a research note on Monday, June 30th. Finally, Bank of America reduced their price objective on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research note on Wednesday, June 11th. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $383.08.

United Therapeutics Trading Down 1.8%

Shares of NASDAQ UTHR traded down $5.32 during midday trading on Friday, reaching $292.01. The company's stock had a trading volume of 322,671 shares, compared to its average volume of 442,719. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $417.82. The stock has a market capitalization of $13.17 billion, a price-to-earnings ratio of 11.65, a PEG ratio of 6.31 and a beta of 0.53. The stock has a 50 day simple moving average of $300.42 and a 200-day simple moving average of $317.89.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. The business had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The firm's revenue for the quarter was up 17.2% on a year-over-year basis. During the same period in the previous year, the company earned $6.17 earnings per share. As a group, equities analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 12,000 shares of the company's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $325.37, for a total value of $3,904,440.00. Following the transaction, the chief financial officer directly owned 8,118 shares in the company, valued at $2,641,353.66. The trade was a 59.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Richard Giltner sold 3,036 shares of the business's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total transaction of $879,225.60. Following the completion of the sale, the director directly owned 19,384 shares of the company's stock, valued at approximately $5,613,606.40. The trade was a 13.54% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 73,681 shares of company stock valued at $22,140,089. Corporate insiders own 10.30% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.